Contact this trialFirst, we need to learn more about you.
Immunomodulator
Ocrelizumab vs Fingolimod for Pediatric Multiple Sclerosis
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial will compare the safety and efficacy of two drugs for treating multiple sclerosis in children and adolescents aged 10-18.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.